The FDA approved the first Ebola vaccine

The Ervebo vaccine was involved in a two-year study conducted during the Ebola epidemic in Guinea, along with Sierra Leone and Liberia that had more than 11,000 deaths in that time frame.

The FDA has formally approved Ebola-related vaccines.

While the Ebola virus disease in the US remains low, the US government remains committed to fighting the Ebola outbreak in Africa, including the current outbreak in the Democratic Republic of Congo.

Anna Abram, deputy commissioner of FDA policy and international affairs, said: 'Our approval is an important step in our continued effort to fight Ebola in close cooperation with our partners. International cooperation such as World Health Organization '.

Ervebo is a single-dose injection used by WHO in 2018 as a investigative vaccine to help fight the world's second largest Ebola epidemic. The virus is transmitted by direct contact with the blood, body fluids and tissues of infected people or animals, as well as contact with contaminated surfaces and materials. Symptoms may appear as soon as two days or up to 21 days after exposure and may include fever, fatigue, muscle aches, headache and sore throat.

Severe symptoms may include vomiting, diarrhea, rash, kidney problems, or liver and bleeding problems.

Following Guinea research and a number of vaccine safety investigations, the FDA issued an order to help facilitate vaccine development.

Earlier, the European Pharmaceutical Commission approved the circulation of the world's first Ervebo (rVSV -G-ZEBOV-GP) vaccine to prevent Ebola in the world. Ervebo vaccine was researched and developed by Merck & Co.

The latest Ebola epidemic killed more than 2,100 people in the world in mid-2018. This is the second largest outbreak in history, after the 2013-2016 epidemic in West Africa that killed more than 11,300 people. .

• The first Ebola vaccine was approved for circulation